MINI REVIEW article
Front. Oncol.
Sec. Head and Neck Cancer
This article is part of the Research TopicReviews in Head and Neck CancersView all 6 articles
Prognostic Biomarkers in Oral Squamous Cell Carcinoma: Current Evidence and Future Directions
Provisionally accepted
- University Medical Center Göttingen, Göttingen, Germany
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Oral squamous cell carcinoma (OSCC) exhibits significant prognostic heterogeneity. This has prompted extensive research into biomarkers that can predict clinical outcomes beyond conventional staging systems. This mini review summarizes findings from the existing literature to provide a comprehensive examination of the prognostic significance of malignancy and progression factors in OSCC, offering insights into future perspectives. There is clear evidence that molecular and protein-based biomarkers, in addition to established clinical and histopathological features, such as lymph node involvement, extranodal spread, and depth of invasion, strongly correlate with overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS). Integrating different gene expression signatures, microRNA (miRNA) profiles, and changes in intracellular signaling pathways enables more differentiated risk stratification. Protein biomarkers such as cyclin D1, trophoblast cell surface antigen 2 (TROP2), urokinase-type plasminogen activator receptor (uPAR), and E-cadherin have been shown to provide clinically useful prognostic information. These results underscore the importance of incorporating biomarkers into individualized risk stratification to enhance personalized treatment regimens and outcomes for OSCC patients. Currently, however, established clinical and histopathological parameters, as well as a limited number of validated molecular profiles, remain the most reliable prognostic indicators. While identifying new biomarkers is promising, establishing standardized protocols and implementing careful prospective validation are essential to ensuring their seamless integration into standard clinical practice.
Keywords: oral squamous cell carcinoma, OSCC, prognostic factors, malignancy, progression, risk stratification
Received: 25 Aug 2025; Accepted: 21 Nov 2025.
Copyright: © 2025 Brockmeyer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Phillipp Brockmeyer, ph.brockmeyer@gmail.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.